APO-MIDODRINE TABLET
国家: 加拿大
语言: 英文
来源: Health Canada
产品特点
(SPC)
16-10-2018
该产品的某些文档当前不可用，您可以向我们的客户服务发送请求，我们将在获得它们后尽快通知您。
发送请求。
发送请求。
有效成分:
MIDODRINE HYDROCHLORIDE
可用日期:
APOTEX INC
ATC代码:
C01CA17
INN（国际名称）:
MIDODRINE
剂量:
2.5MG
药物剂型:
TABLET
组成:
MIDODRINE HYDROCHLORIDE 2.5MG
给药途径:
ORAL
每包单位数:
100
处方类型:
Prescription
治疗领域:
ALPHA-ADRENERGIC AGONISTS
產品總結:
Active ingredient group (AIG) number: 0123066001; AHFS:
授权状态:
APPROVED
授权日期:
2006-03-13
产品特点
Page 1 of 23
PRODUCT MONOGRAPH
Pr
APO-MIDODRINE
MIDODRINE HYDROCHLORIDE TABLETS USP
2.5 MG AND 5 MG
VASOPRESSOR
APOTEX INC. DATE OF PREPARATION
150 SIGNET DRIVE OCTOBER 16, 2018
TORONTO, ONTARIO
M9L 1T9
CONTROL NO. 219481
Page 2 of 23
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 4
SUMMARY PRODUCT INFORMATION
.............................................................................
4
INDICATIONS AND CLINICAL USE
...................................................................................
4
CONTRAINDICATIONS
........................................................................................................
5
WARNINGS AND PRECAUTIONS
.......................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
7
DRUG INTERACTIONS
.........................................................................................................
9
DOSAGE AND ADMINISTRATION
...................................................................................
10
OVERDOSAGE
......................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
................................................................. 11
STORAGE AND STABILITY
...............................................................................................
12
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................. 13
PART II: SCIENTIFIC INFORMATION
.............................................................................
14
PHARMACEUTICAL INFORMATION
...............................................................................
14
CLINICAL TRIALS
...............................................................................................................
16
DETAILED PHARMACOLOGY
...........................................
阅读完整的文件
